Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Wallentin

Showing results (141-150 of 186) with videos related to

Pageof 19
Sort By:
American Heart Journal|December 1, 1992
Thrombolysis with recombinant human tissue-type plasminogen activator during instability in coronary artery disease: effect on myocardial ischemia and need for coronary revascularization. TRIC Study GroupJ E Karlsson, U Berglund, A Björkholm, et al.
Thrombosis and Haemostasis|May 13, 2014
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' valueL Wallentin, A Himmelmann, R F Storey, et al.
Journal of Internal Medicine|March 1, 1994
Insulin treatment improves microalbuminuria and other cardiovascular risk factors in patients with type 2 diabetes mellitusT Lindström, A G Olsson, H von Schenck, et al.
Clinical Physiology (Oxford, England)|September 1, 1992
Exercise echocardiography: a methodological study comparing peak-exercise and post-exercise image informationP Blomstrand, J Engvall, J E Karlsson, et al.
European Heart Journal|February 1, 2003
Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery diseaseJ Oldgren, L Wallentin, L Grip, et al.
International Journal of Cardiology|November 1, 1993
ST-changes in ECG at rest or during exercise indicate a high risk of severe coronary lesions after an episode of unstable coronary artery diseaseJ E Karlsson, A Björkholm, E Nylander, et al.
Der Urologe. Ausg. A|January 1, 1982
[Effects of oestrogens on cardiovascular risk factors in patients with carcinoma of the prostate (author's transl)]E Varenhorst, K Carlström, B E Karlberg, et al.
European Heart Journal|July 20, 2002
Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularizationS E Husted, L Wallentin, B Lagerqvist, et al.
Clinical Cardiology|April 5, 2001
The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS studyL Wallentin, D M Dellborg, B Lindahl, et al.
Lakartidningen|March 29, 2001
[Policy document. Catheter-based diagnosis and treatment of coronary diseases]T Nilsson, L Bergfeldt, B Aberg, et al.
Pageof 19

Showing results (141-150 of 186) with videos related to

Sort By:
Pageof 19
American Heart Journal|December 1, 1992
Thrombolysis with recombinant human tissue-type plasminogen activator during instability in coronary artery disease: effect on myocardial ischemia and need for coronary revascularization. TRIC Study GroupJ E Karlsson, U Berglund, A Björkholm, et al.
Thrombosis and Haemostasis|May 13, 2014
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' valueL Wallentin, A Himmelmann, R F Storey, et al.
Journal of Internal Medicine|March 1, 1994
Insulin treatment improves microalbuminuria and other cardiovascular risk factors in patients with type 2 diabetes mellitusT Lindström, A G Olsson, H von Schenck, et al.
Clinical Physiology (Oxford, England)|September 1, 1992
Exercise echocardiography: a methodological study comparing peak-exercise and post-exercise image informationP Blomstrand, J Engvall, J E Karlsson, et al.
European Heart Journal|February 1, 2003
Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery diseaseJ Oldgren, L Wallentin, L Grip, et al.
International Journal of Cardiology|November 1, 1993
ST-changes in ECG at rest or during exercise indicate a high risk of severe coronary lesions after an episode of unstable coronary artery diseaseJ E Karlsson, A Björkholm, E Nylander, et al.
Der Urologe. Ausg. A|January 1, 1982
[Effects of oestrogens on cardiovascular risk factors in patients with carcinoma of the prostate (author's transl)]E Varenhorst, K Carlström, B E Karlberg, et al.
European Heart Journal|July 20, 2002
Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularizationS E Husted, L Wallentin, B Lagerqvist, et al.
Clinical Cardiology|April 5, 2001
The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS studyL Wallentin, D M Dellborg, B Lindahl, et al.
Lakartidningen|March 29, 2001
[Policy document. Catheter-based diagnosis and treatment of coronary diseases]T Nilsson, L Bergfeldt, B Aberg, et al.
Pageof 19